Source comparison
Time Thymosin Alpha-1 Doses: Comparison by Protocol
Standard Immune Support 1.6mg 2× weekly (Mon/Thu) 3.2mg/week Optimal. Allows full 72-hour T-cell differentiation between doses General immune modulation research, chronic infection models Most validated in published literature; lowest cost per cycle while main
This comparison does not assign a generated winner or score.
- Standard Immune Support
- 1.6mg
- 2× weekly (Mon/Thu)
- 3.2mg/week
- Optimal. Allows full 72-hour T-cell differentiation between doses
- General immune modulation research, chronic infection models
- Most validated in published literature; lowest cost per cycle while maintaining efficacy
- High-Dose Acute Protocol
- 3.2–6.4mg
- 2× weekly (Tue/Fri)
- 6.4–12.8mg/week
- Acceptable. Higher dose compensates for potential receptor saturation
- Acute immune challenge models, post-surgical immune recovery studies
- Used in hepatitis B and hepatitis C clinical trials; requires close monitoring for diminishing returns
- Conservative Low-Dose
- 0.8–1.6mg
- 1× weekly
- 0.8–1.6mg/week
- Suboptimal. Single weekly dose creates inconsistent thymic stimulation
- Maintenance phases after initial immune restoration, elderly populations
- Not well-studied in controlled trials; may be insufficient for measurable immune marker changes
- Daily Dosing (Non-Standard)
- 0.5–1.0mg
- Daily
- 3.5–7.0mg/week
- Poor. Peptide re-administered before thymic maturation completes
- Not recommended for research use
- No published evidence of superior outcomes vs twice-weekly; wastes peptide by overlapping with active thymic cycles